Targeting CD40 enhances antibody- and CD8-mediated protection against respiratory syncytial virus infection

Area of Science:

• Immunology
• Vaccinology
• Virology

Background:

• Respiratory Syncytial Virus (RSV) is a major cause of infant hospitalization, with no licensed vaccine currently available despite extensive research.
• Developing an effective and safe RSV vaccine remains a significant challenge in public health.

Purpose of the Study:

• To evaluate a novel adenoviral vector vaccine expressing a fusion protein of RSV and CD40 ligand in a mouse model.
• To assess the vaccine's efficacy in preventing RSV infection and associated respiratory disease, and to characterize the immune responses induced.

Main Methods:

• An adenoviral vector was engineered to deliver the RSV fusion (F) protein fused with CD40 ligand into BALB/c mice.
• The immune response, protection against RSV challenge, and long-term immunity were compared to a formaldehyde-inactivated vaccine.
• Levels of neutralizing antibodies and memory CD8 T cells were quantified.

Main Results:

• The vectored vaccine provided effective protection against RSV without inducing enhanced respiratory disease, a known issue with some inactivated vaccines.
• Robust induction of neutralizing antibodies and memory CD8 T cells was observed with the vectored vaccine, but not the inactivated vaccine.
• Long-lasting protection was achieved, attributed to sustained levels of effector memory CD8 T cells up to 3 months post-vaccination.

Conclusions:

• Adenoviral vector delivery of RSV F protein fused with CD40 ligand is a promising strategy for developing a safe and effective RSV vaccine.
• The CD40 ligand acts as both an adjuvant and an antigen-targeting molecule, enhancing protective immunity and memory responses.
• This approach offers a potential solution for long-lasting protection against RSV, addressing a critical unmet medical need.